Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

Cardiovascular Research

Volumn 55, Issue 3, 2002, Pages 506-519

  Bolli, Roberto ^a   Shinmura, Ken ^a   Tang, Xian Liang ^a   Kodani, Eitaro ^a   Xuan, Yu Ting ^a   Guo, Yiru ^a   Dawn, Buddhadeb ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Ischemia; Nitric oxide; Preconditioning; Reperfusion

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; CYCLOOXYGENASE 2; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; ENZYME INHIBITOR; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; PROTEIN; CYCLOOXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; MEMBRANE PROTEIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NOS2A PROTEIN, HUMAN; PROSTAGLANDIN SYNTHASE; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

BIOSYNTHESIS; CARCINOGENESIS; CELL DEATH; CELL PROTECTION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; EXERCISE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOMEOSTASIS; INFLAMMATION; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REPERFUSION INJURY; REVIEW; STUNNED HEART MUSCLE; SYNTHESIS; TREATMENT PLANNING; ANIMAL; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; METABOLISM; PHYSIOLOGY; TIME;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMAN; ISCHEMIC PRECONDITIONING, MYOCARDIAL; ISOENZYMES; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; NITRIC-OXIDE SYNTHASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HUMANS; MEMBRANE PROTEINS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036023621     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00414-5     Document Type: Review

References (131)

1. ATP channel
2. The late phase of preconditioning
3. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning
4. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits
5. The nitric oxide hypothesis of late preconditioning
6. The late phase of ischemic preconditioning is abrogated by targeted disruption of the iNOS gene
7. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
8. Cyclooxygenases 1 and 2
9. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2
10. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells
11. 2 metabolites regulate inducible nitric oxide synthase in myocytes
12. Interleukin-1β regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes
13. Serotonin-induced coronary contraction increases after blood cardioplegia-reperfusion: Role of COX-2 expression
14. Phorbol ester stimulates cyclooxygenase-2 expression and prostanoid production in cardiac myocytes
15. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: Activation of cyclooxygenase by nitric oxide
16. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia
17. Interleukin-1 beta activates expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: Platelet-activating factor as a preferential mediator of cyclooxygenase-2 expression
18. Co-induction of nitric oxide synthase and cyclo-oxygenase: Interactions between nitric oxide and prostanoids
19. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation
20. Upregulation of COX-2 during cardiac allograft rejection
21. Cyclooxygenase-2 induction in congestive heart failure: Friend or foe?
22. Superoxide attenuates macrophage apoptosis by NF-kappa B and AP-1 activation that promotes cyclooxygenase-2 expression
23. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway
24. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element
25. Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells
26. Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis
27. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells
28. 3 in the nonischemic and ischemic pig heart
29. Iloprost (ZK 36374) enhances recovery of regional myocardial function during reperfusion after coronary artery occlusion and reperfusion in the pig
30. Myocardial ischaemia and reperfusion in the anaesthetized pig: Reduction of infarct size and myocardial enzyme release by the stable prostacyclin analogue iloprost
31. Stimulation of endogenous prostacyclin protects the reperfused ischemic pig myocardium from ischemic injury
32. 1 and cardiac arrhythmia
33. 2: Preliminary results
34. Prostaglandins and myocardial noradrenaline overflow after sympathetic nerve stimulation during ischemia and reperfusion
35. 3 receptors in the reperfused ischemic pig heart
36. 3 receptor reduces myocardial infarct size in rodents
37. 2 on myocardial infarct size after coronary occlusion in conscious dogs
38. 1 inhibition of ischemia-induced neutrophil activation
39. 1: Inhibition of neutrophil migration and activation
40. 0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels
41. Sulprostone-induced reduction of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels
42. 2+ current of rabbits
43. Prostacyclin: Antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK 36374 during coronary artery occlusion and reperfusion in anaesthetised greyhounds
44. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart
45. 1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model
46. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits
47. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide
48. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism
49. The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: An overview
50. Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors
51. Demonstration of an early and a late phase of ischemic preconditioning in mice
52. Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice
53. ATP channels
54. 1 receptor agonists is iNOS-dependent [abstract]
55. Adenosine receptor involvement in a delayed phase of myocardial protection 24 h after ischemic preconditioning
56. 1 receptor activation in the rabbit
57. 3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms
58. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning
59. Direct evidence that protein kinase C plays an essential role in the development of late preconditioning against myocardial stunning in conscious rabbits and that epsilon is the isoform involved
60. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits
61. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits
62. Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits
63. Structure of the human cyclo-oxygenase-2 gene
64. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis
65. Nitric oxide activates cyclooxygenase enzymes
66. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation
67. Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase
68. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase
69. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells
70. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide
71. Regulation of the expression of cyclooxygenase-2 by nitric oxide in rat peritoneal macrophages
72. Regulation of cytosolic COX-2 and prostaglandin E2 production by nitric oxide in activated murine macrophages
73. Nitric oxide synthase/COX cross-talk: Nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production
74. Interaction between nitric oxide and prostaglandin H synthase
75. Nitric oxide: A prostaglandin H synthase 1 and 2 reducing cosubstrate that does not stimulate cyclooxygenase activity or prostaglandin H synthase expression in murine macrophages
76. Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: Investigations using the selective inhibitors, 1400W and celecoxib
77. Role of cyclic guanosine monophosphate in nitric oxide-dependent late preconditioning in conscious rabbits [abstract]
78. Aspirin, prostaglandins and platelet function: Pharmacology and thrombosis prevention
79. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
80. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate
81. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein
82. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin
83. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
84. Aspirin and salicylate: An old remedy with a new twist
85. The preconditioning phenomenon: A tool for the scientist or a clinical reality?
86. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty
87. The effect of aspirin on the late phase of ischemia preconditioning against myocardial stunning in conscious rabbits [abstract]
88. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
89. Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products
90. Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids
91. Role of lipoxygenase metabolites in ischemic preconditioning
92. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning
93. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
94. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
95. Cyclooxygenase-2: An essential regulator of NO-mediated apoptosis
96. Beneficial effects of iloprost in the stunned canine myocardium
97. Prostaglandin E1 attenuates postischemic contractile dysfunction after brief coronary occlusion and reperfusion
98. Eicosanoids and the ischemic myocardium
99. Prostanoid receptors: Structures, properties, and functions
100. Prostaglandin E receptors in cardiac sarcolemmal: Identification and coupling to adenylate cyclase
101. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: An overview of a decade of research
102. Delayed ischemic preconditioning is mediated by opening of ATP-sensitive potassium channels in the rabbit heart
103. ATP channels in late preconditioning against myocardial stunning and infarction in rabbits
104. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
105. Strong nuclear factor-κB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex
106. Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat
107. Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma
108. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells
109. Prostaglandin E1 transported into cells blocks the apoptotic signals induced by nerve growth factor deprivation
110. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
111. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
112. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure
113. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage
114. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia
115. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
116. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
117. Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival
118. Inducible cyclooxygenase may have anti-inflammatory properties
119. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease [review]
120. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
121. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress
122. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis
123. Risk of cardiovascular events associated with selective COX-2 inhibitors
124. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells
125. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
126. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex
127. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: Implications for Alzheimer's disease
128. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group
129. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
130. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
131. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue